论文部分内容阅读
目的 :研究鼻咽癌患者放射性口腔粘膜炎的防治。方法 :对 42例鼻咽癌放疗患者随机分为两组 ,思密达 (Smecta --SMT)和呋喃西林 (Furanilinum - -FURA)组各 2 1例。前者在放疗期间每日含漱思密达 ;后者每日含嗽 0 0 2 %呋喃西林液。两组均用药至放疗结束。结果 :SMT组放射性口腔粘膜炎发生率为 33 3% ;FURA组为 76 2 %。两组相比有显著性差异 (P <0 0 5 )。FURA组发生口腔粘膜炎的严重程度较SMT组严重 ,两组严重程度分级构成具有显著性差异 (P <0 0 5 )。两组出现口腔粘膜炎的时相前者晚于后者。结论 :思密达能有效地防治放射性口腔粘膜炎的发生 ,减轻症状 ,从而保证放疗计划的顺利完成。
Objective: To study the prevention and treatment of radioactive oral mucositis in patients with nasopharyngeal carcinoma. Methods: Forty - two patients with radiotherapy of nasopharyngeal carcinoma were randomly divided into two groups: 21 cases each with Smecta - SMT and Furanilinum - FURA groups. The former contains daily Smectite during radiotherapy; the latter contains 200% Furanicillin daily. Both groups were treated with radiotherapy to the end. Results: The incidence of radioactive oral mucositis was 33.3% in SMT group and 76.2% in FURA group. There was significant difference between the two groups (P <0 05). The incidence of oral mucositis in FURA group was more serious than that in SMT group, and there was a significant difference (P <0 05) in the grading of severity between the two groups. The two groups of oral mucositis appear later than the latter. Conclusion: Smecta could effectively prevent and treat radiation-induced oral mucositis and relieve symptoms, thus ensuring the successful completion of radiotherapy.